Hsu JT - Search Results

1

Aurora kinase A inhibitors: identification, SAR exploration and molecular modeling of 6,7-dihydro-4H-pyrazolo-[1,5-a]pyrrolo[3,4-d]pyrimidine-5,8-dione scaffold.

Coumar MS, Wu JS, Leou JS, Tan UK, Chang CY, Chang TY, Lin WH, Hsu JT, Chao YS, Wu SY, Hsieh HP. Coumar MS, et al. Among authors: hsu jt. Bioorg Med Chem Lett. 2008 Mar 1;18(5):1623-7. doi: 10.1016/j.bmcl.2008.01.068. Epub 2008 Jan 19. Bioorg Med Chem Lett. 2008. PMID: 18243698

2

Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies.

Mahindroo N, Wang CC, Liao CC, Huang CF, Lu IL, Lien TW, Peng YH, Huang WJ, Lin YT, Hsu MC, Lin CH, Tsai CH, Hsu JT, Chen X, Lyu PC, Chao YS, Wu SY, Hsieh HP. Mahindroo N, et al. Among authors: hsu jt, hsu mc. J Med Chem. 2006 Feb 9;49(3):1212-6. doi: 10.1021/jm0510373. J Med Chem. 2006. PMID: 16451087

3

Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities.

Lu IL, Huang CF, Peng YH, Lin YT, Hsieh HP, Chen CT, Lien TW, Lee HJ, Mahindroo N, Prakash E, Yueh A, Chen HY, Goparaju CM, Chen X, Liao CC, Chao YS, Hsu JT, Wu SY. Lu IL, et al. Among authors: hsu jt. J Med Chem. 2006 May 4;49(9):2703-12. doi: 10.1021/jm051129s. J Med Chem. 2006. PMID: 16640330

4

Structure-based drug design of novel Aurora kinase A inhibitors: structural basis for potency and specificity.

Coumar MS, Leou JS, Shukla P, Wu JS, Dixit AK, Lin WH, Chang CY, Lien TW, Tan UK, Chen CH, Hsu JT, Chao YS, Wu SY, Hsieh HP. Coumar MS, et al. Among authors: hsu jt. J Med Chem. 2009 Feb 26;52(4):1050-62. doi: 10.1021/jm801270e. J Med Chem. 2009. PMID: 19140666

5

Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists.

Lin CH, Peng YH, Coumar MS, Chittimalla SK, Liao CC, Lyn PC, Huang CC, Lien TW, Lin WH, Hsu JT, Cheng JH, Chen X, Wu JS, Chao YS, Lee HJ, Juo CG, Wu SY, Hsieh HP. Lin CH, et al. Among authors: hsu jt. J Med Chem. 2009 Apr 23;52(8):2618-22. doi: 10.1021/jm801594x. J Med Chem. 2009. PMID: 19301897

6

Identification, SAR studies, and X-ray co-crystallographic analysis of a novel furanopyrimidine aurora kinase A inhibitor.

Coumar MS, Tsai MT, Chu CY, Uang BJ, Lin WH, Chang CY, Chang TY, Leou JS, Teng CH, Wu JS, Fang MY, Chen CH, Hsu JT, Wu SY, Chao YS, Hsieh HP. Coumar MS, et al. Among authors: hsu jt. ChemMedChem. 2010 Feb 1;5(2):255-67. doi: 10.1002/cmdc.200900339. ChemMedChem. 2010. PMID: 20039358

7

Anti-influenza drug discovery: structure-activity relationship and mechanistic insight into novel angelicin derivatives.

Yeh JY, Coumar MS, Horng JT, Shiao HY, Kuo FM, Lee HL, Chen IC, Chang CW, Tang WF, Tseng SN, Chen CJ, Shih SR, Hsu JT, Liao CC, Chao YS, Hsieh HP. Yeh JY, et al. Among authors: hsu jt. J Med Chem. 2010 Feb 25;53(4):1519-33. doi: 10.1021/jm901570x. J Med Chem. 2010. PMID: 20092255

8

Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.

Coumar MS, Chu CY, Lin CW, Shiao HY, Ho YL, Reddy R, Lin WH, Chen CH, Peng YH, Leou JS, Lien TW, Huang CT, Fang MY, Wu SH, Wu JS, Chittimalla SK, Song JS, Hsu JT, Wu SY, Liao CC, Chao YS, Hsieh HP. Coumar MS, et al. Among authors: hsu jt. J Med Chem. 2010 Jul 8;53(13):4980-8. doi: 10.1021/jm1000198. J Med Chem. 2010. PMID: 20550212

9

Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency.

Wu CH, Coumar MS, Chu CY, Lin WH, Chen YR, Chen CT, Shiao HY, Rafi S, Wang SY, Hsu H, Chen CH, Chang CY, Chang TY, Lien TW, Fang MY, Yeh KC, Chen CP, Yeh TK, Hsieh SH, Hsu JT, Liao CC, Chao YS, Hsieh HP. Wu CH, et al. Among authors: hsu jt, hsu h. J Med Chem. 2010 Oct 28;53(20):7316-26. doi: 10.1021/jm100607r. J Med Chem. 2010. PMID: 20961149

10

Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).

Lin WH, Hsieh SY, Yen SC, Chen CT, Yeh TK, Hsu T, Lu CT, Chen CP, Chen CW, Chou LH, Huang YL, Cheng AH, Chang YI, Tseng YJ, Yen KR, Chao YS, Hsu JT, Jiaang WT. Lin WH, et al. Among authors: hsu t, hsu jt. Bioorg Med Chem. 2011 Jul 15;19(14):4173-82. doi: 10.1016/j.bmc.2011.06.016. Epub 2011 Jun 13. Bioorg Med Chem. 2011. PMID: 21708468

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

577 results

Search Page

Filters